{
    "paper_id": "PMC7197241",
    "metadata": {
        "title": "ACEI inhibitors and ARBs do not increase severity of COVID-19",
        "authors": []
    },
    "body_text": [
        {
            "text": "ACEI inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) do not appear to increase the severity of COVID-19 infections or the risk of death, according to findings of a study published in JAMA Cardiology.",
            "cite_spans": [],
            "section": "",
            "ref_spans": []
        },
        {
            "text": "This retrospective case series in 1178 patients in Wuhan, China, hospitalised with confirmed COVID-19 infections in March 2020 assessed the association between ACEI or ARB treatment for hypertension and the risks of severe infection and death.",
            "cite_spans": [],
            "section": "",
            "ref_spans": []
        },
        {
            "text": "Overall, 30.7% of patients had hypertension and 31.8% of these patients were receiving ACEI/ARB treatment. The rate of death during hospitalisation was 11% overall and 21.3% in patients with hypertension.",
            "cite_spans": [],
            "section": "",
            "ref_spans": []
        },
        {
            "text": "The proportion of patients with hypertension receiving ACEI/ARB treatment was similar in those with and without severe infections (32.9% vs 30.7%) and in those who died versus survivors (27.3% vs 33.0%). There were no significant differences in the rates of severe versus nonsevere infection in ACEI users (9.2%  vs 10.1%) or ARB users (24.9% vs 21.2%), or between rates of death versus survival (9.1% vs 9.8% and 19.5% vs 23.9%, respectively).",
            "cite_spans": [],
            "section": "",
            "ref_spans": []
        },
        {
            "text": "\"The current findings did not identify an association between treatment with ACEIs/ARBs and either severity or clinical outcomes of COVID-19 hospitalizations in patients with hypertension. These data support current guidelines and societal recommendations for treating hypertension during the COVID-19 pandemic,\" concluded the authors.",
            "cite_spans": [],
            "section": "",
            "ref_spans": []
        }
    ],
    "ref_entries": {},
    "back_matter": [],
    "bib_entries": {
        "BIBREF0": {
            "title": "",
            "authors": [],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": null,
            "other_ids": {
                "DOI": []
            }
        }
    }
}